Roche Receives CE Mark for Alzheimer’s Disease Blood Test
Roche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Roche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants.
The mRNA-based test aims to provide objective data to help clinicians distinguish between psychiatric conditions that often share symptoms.
Amplified Sciences has received CAP accreditation for its clinical laboratory, enabling broader commercial deployment of its PanCystPro assay for pancreatic cancer risk assessment, the company announced.
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
CareDx will acquire Naveris for $160 million, adding a Medicare-reimbursed liquid biopsy platform for viral-mediated cancer monitoring to its precision medicine portfolio.
This clinical lab conference spotlight looks at why ADLM 2026 belongs on the radar for CLP readers. From the scientific program to the Clinical Lab Expo, the event offers practical ideas, fresh technology, and real conversations for people working across diagnostics and laboratory medicine. For lab professionals who want useful insight, sharper perspective, and stronger industry connections, this is a smart place to be.